ADMA Biologics (ADMA) vs Beam Therapeutics (BEAM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Beam Therapeutics (BEAM) has outperformed ADMA Biologics (ADMA) over the past year, losing 1.4% versus a loss of 27.5%. Over five years, ADMA leads with a +821.8% price change compared with -73.4% for BEAM. Beam Therapeutics is the larger company by market cap ($2.56 billion vs $2.27 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADMA | BEAM |
|---|---|---|
| Share price | $10.14 | $24.77 |
| Market cap | $2.27B | $2.56B |
| 1-day change | -0.39% | -1.82% |
| YTD return | -44.41% | -10.64% |
| 1-year return | -27.52% | -1.43% |
| 5-year return | +821.82% | -73.41% |
| P/E ratio (TTM) | 14.49 | — |
| Forward P/E | 10.75 | — |
| EPS (TTM) | $0.70 | $-0.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $139.74M |
| Revenue growth (YoY) | — | +120.01% |
| Net income (latest FY) | — | $-79.99M |
| Operating margin | — | -274.57% |
| Net margin | — | -57.24% |
| 52-week high | $20.46 | $38.26 |
| 52-week low | $7.21 | $20.23 |
| Distance from 52-week high | -50.44% | -35.26% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +67.65% | +110.54% |
| Average volume | 2.62M | 1.91M |
| Shares outstanding | 223.98M | 103.29M |
| Employees | 640 | 540 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BEAM has outperformed ADMA by 26.1 percentage points over the past year.
About ADMA Biologics
ADMA stock →ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 640 employees
About Beam Therapeutics
BEAM stock →Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 540 employees
ADMA vs BEAM FAQ
Which is bigger, ADMA Biologics or Beam Therapeutics?
Beam Therapeutics (BEAM) is larger, with a market capitalization of $2.56B compared with $2.27B for ADMA Biologics (ADMA).
Which stock has performed better over the past year, ADMA or BEAM?
BEAM returned -1.43% over the past 12 months, compared with -27.52% for ADMA (price return, excluding dividends). Past performance does not predict future results.
Are ADMA Biologics and Beam Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.